AI agent aims to close hepatitis b treatment gap
NCT ID NCT07520123
First seen Apr 12, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests an intelligent agent (Union-Agent) to help people with chronic hepatitis B who have been diagnosed but haven't started antiviral treatment. The goal is to see if the agent can increase the number of eligible patients who begin treatment within six months. About 2000 adults who are treatment-naive or have not taken medication for 6 months will participate across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Infectious Disease, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.